FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3007769928> ?p ?o ?g. }

• W3007769928 endingPage "46" @default.
• W3007769928 startingPage "40" @default.
• W3007769928 abstract "Abstract The incidence of IBD is increasing in Eastern countries. The anti‐TNF‐α biological agents are available in patients with severely active IBD. Recently, the vedolizumab was approved by Taiwan Food and Drug Administration (TFDA). The efficacy and safety of vedolizumab in real‐world practice for Asia regions is uncertain. Our primary endpoint is to evaluate the efficacy of vedolizumab for TNF‐α exposure and naive patients during induction phase. The secondary endpoints are adverse events, infection, and emergent surgery during induction. We conducted a retrospective observational cohort study from November 2017 to April 2019 in our hospital. We enrolled patients receiving vedolizumab with or without previous anti‐TNF‐α agent exposure. The study results of continuous and categorical variables are presented as median (interquartile range [IQR]), with the IQR presented as 25th percentile to 75th percentile, and number (percentage), respectively. Categorical variables were compared with Fisher's exact test or Pearson's chi‐square test, and continuous variables were compared with a Mann‐Whitney U test. Twenty‐four patients received vedolizumab from November 2017 to April 2019. Sixteen patients had finished the postinduction phase of the clinical evaluation. None of the patients discontinued vedolizumab due to an adverse drug reaction. The study group all fulfilled the criteria for clinical response and two of them achieved clinical remission. 50% of the patients could successfully discontinue systemic and topical steroid treatment. Three patients from CD group had endoscopic remission. Compare CD to UC patients, the efficacy of vedolizumab is comparable to both groups, but endoscopic response is slightly better in CD group. One patient developed systemic infection (urinary tract infection). None of tuberculosis complex infection or hepatitis B flare up observed during follow‐up period. In this study, we offer our real‐world experience of vedolizumab and suggest that the use of vedolizumanb is safe and effective. Moreover, 50% of steroid‐dependent patients can discontinue steroid after vedolizumab induction. This can be addressed in the future study." @default.
• W3007769928 created "2020-03-06" @default.
• W3007769928 creator A5017681417 @default.
• W3007769928 creator A5026166606 @default.
• W3007769928 creator A5034343141 @default.
• W3007769928 creator A5065299734 @default.
• W3007769928 creator A5073406697 @default.
• W3007769928 creator A5073617752 @default.
• W3007769928 date "2020-03-12" @default.
• W3007769928 modified "2023-09-27" @default.
• W3007769928 title "Real‐world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: A single tertiary medical center experience in Central Taiwan" @default.
• W3007769928 cites W1975218841 @default.
• W3007769928 cites W1986652365 @default.
• W3007769928 cites W2000295854 @default.
• W3007769928 cites W2011837830 @default.
• W3007769928 cites W2012880786 @default.
• W3007769928 cites W2027091732 @default.
• W3007769928 cites W2031193040 @default.
• W3007769928 cites W2056873984 @default.
• W3007769928 cites W2058077753 @default.
• W3007769928 cites W2071662837 @default.
• W3007769928 cites W2072640801 @default.
• W3007769928 cites W2077531651 @default.
• W3007769928 cites W2112635226 @default.
• W3007769928 cites W2160619682 @default.
• W3007769928 cites W2162805528 @default.
• W3007769928 cites W2313671791 @default.
• W3007769928 cites W2318078681 @default.
• W3007769928 cites W2321902261 @default.
• W3007769928 cites W2330470789 @default.
• W3007769928 cites W2337892261 @default.
• W3007769928 cites W2523706394 @default.
• W3007769928 cites W2560112556 @default.
• W3007769928 cites W2625272402 @default.
• W3007769928 cites W2626039069 @default.
• W3007769928 cites W2740875885 @default.
• W3007769928 cites W2765680011 @default.
• W3007769928 cites W2766046358 @default.
• W3007769928 cites W2789693626 @default.
• W3007769928 cites W2794595980 @default.
• W3007769928 cites W2895702868 @default.
• W3007769928 cites W3149527659 @default.
• W3007769928 cites W4210662453 @default.
• W3007769928 cites W4295333203 @default.
• W3007769928 doi "https://doi.org/10.1002/aid2.13188" @default.
• W3007769928 hasPublicationYear "2020" @default.
• W3007769928 type Work @default.
• W3007769928 sameAs 3007769928 @default.
• W3007769928 citedByCount "6" @default.
• W3007769928 countsByYear W30077699282021 @default.
• W3007769928 countsByYear W30077699282022 @default.
• W3007769928 countsByYear W30077699282023 @default.
• W3007769928 crossrefType "journal-article" @default.
• W3007769928 hasAuthorship W3007769928A5017681417 @default.
• W3007769928 hasAuthorship W3007769928A5026166606 @default.
• W3007769928 hasAuthorship W3007769928A5034343141 @default.
• W3007769928 hasAuthorship W3007769928A5065299734 @default.
• W3007769928 hasAuthorship W3007769928A5073406697 @default.
• W3007769928 hasAuthorship W3007769928A5073617752 @default.
• W3007769928 hasBestOaLocation W30077699281 @default.
• W3007769928 hasConcept C119060515 @default.
• W3007769928 hasConcept C126322002 @default.
• W3007769928 hasConcept C167135981 @default.
• W3007769928 hasConcept C197934379 @default.
• W3007769928 hasConcept C203092338 @default.
• W3007769928 hasConcept C2776207728 @default.
• W3007769928 hasConcept C2778260677 @default.
• W3007769928 hasConcept C2779134260 @default.
• W3007769928 hasConcept C2780479503 @default.
• W3007769928 hasConcept C535046627 @default.
• W3007769928 hasConcept C71924100 @default.
• W3007769928 hasConceptScore W3007769928C119060515 @default.
• W3007769928 hasConceptScore W3007769928C126322002 @default.
• W3007769928 hasConceptScore W3007769928C167135981 @default.
• W3007769928 hasConceptScore W3007769928C197934379 @default.
• W3007769928 hasConceptScore W3007769928C203092338 @default.
• W3007769928 hasConceptScore W3007769928C2776207728 @default.
• W3007769928 hasConceptScore W3007769928C2778260677 @default.
• W3007769928 hasConceptScore W3007769928C2779134260 @default.
• W3007769928 hasConceptScore W3007769928C2780479503 @default.
• W3007769928 hasConceptScore W3007769928C535046627 @default.
• W3007769928 hasConceptScore W3007769928C71924100 @default.
• W3007769928 hasIssue "1" @default.
• W3007769928 hasLocation W30077699281 @default.
• W3007769928 hasOpenAccess W3007769928 @default.
• W3007769928 hasPrimaryLocation W30077699281 @default.
• W3007769928 hasRelatedWork W1864880157 @default.
• W3007769928 hasRelatedWork W2033059461 @default.
• W3007769928 hasRelatedWork W2063965078 @default.
• W3007769928 hasRelatedWork W2064867978 @default.
• W3007769928 hasRelatedWork W2221971298 @default.
• W3007769928 hasRelatedWork W2341879915 @default.
• W3007769928 hasRelatedWork W3007087481 @default.
• W3007769928 hasRelatedWork W4244220285 @default.
• W3007769928 hasRelatedWork W4249500390 @default.
• W3007769928 hasRelatedWork W4318579187 @default.
• W3007769928 hasVolume "8" @default.
• W3007769928 isParatext "false" @default.

• next